The typical patient with chronic lymphocytic leukemia (CLL)presents to his physician at the time of a routine physicalexamination as an asymptomatic man who has reached the timein his life when he can enjoy the fruits of his working years.He learns from his physician that he has a somewhat enigmatictype of leukemia, the clinical course and outcome of which varyconsiderably from patient to patient, and therefore that hisoutlook is unpredictable. He may be told that some patientslive with the disease for decades and die with (and not becauseof) the disease. He may . . . [Full Text of this Article]
Source Information
From the North ShoreLong Island Jewish Research Institute, Manhasset, N.Y.
This article has been cited by other articles:
Nowakowski, G. S., Hoyer, J. D., Shanafelt, T. D., Zent, C. S., Call, T. G., Bone, N. D., LaPlant, B., Dewald, G. W., Tschumper, R. C., Jelinek, D. F., Witzig, T. E., Kay, N. E.
(2009). Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia. JCO
27: 1844-1849
[Abstract][Full Text]
Hewamana, S., Lin, T. T., Rowntree, C., Karunanithi, K., Pratt, G., Hills, R., Fegan, C., Brennan, P., Pepper, C.
(2009). Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia. JCO
27: 763-769
[Abstract][Full Text]
Gribben, J. G.
(2008). Role of Allogeneic Hematopoietic Stem-Cell Transplantation in Chronic Lymphocytic Leukemia. JCO
26: 4864-4865
[Full Text]
Hauswirth, A. W., Jager, U.
(2008). Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia. haematol
93: 14-19
[Full Text]
Steinberg, M., Adjali, O., Swainson, L., Merida, P., Bartolo, V. D., Pelletier, L., Taylor, N., Noraz, N.
(2004). T-cell receptor-induced phosphorylation of the {zeta} chain is efficiently promoted by ZAP-70 but not Syk. Blood
104: 760-767
[Abstract][Full Text]